Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy.

Autoimmune skin disease occurs in pregnancy, and treatment is often required to control both maternal disease and fetal outcomes. Here we present the available safety data in pregnancy and lactation for medications used to treat autoimmune skin diseases, including cutaneous lupus erythematosus, dermatomyositis, morphea and systemic sclerosis, pemphigus vulgaris, pemphigus foliaceus, and pemphigoid gestationis. A PubMed search of the English-language literature using keywords, "pregnancy" "rheumatic disease," and "connective tissue disease" was performed. Relevant articles found in the search and references were included. Reasonable evidence supports the careful and cautious use of topical steroids, topical calcineurin inhibitors, systemic corticosteroids, hydroxychloroquine, and azathioprine in pregnancy. Case reports or clinical experience suggest intravenous immunoglobulin, dapsone, phototherapy, rituximab, and plasmapheresis may be safe. Several treatment options exist for autoimmune skin disease in pregnancy and lactation, and should be considered when treating these patients. Published 2013. This article is a U.S. Government work and is in the public domain in the USA.

Citation

Inbal Braunstein, Victoria Werth. Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy. Dermatologic therapy. 2013 Jul-Aug;26(4):354-63

PMID: 23914893

search → result